Brolucizumab (also known as RTH258) is a human­ized single-chain antibody fragment that inhibits all isoforms of VEGF-A with a molecular weight of 26 kDa.

“On a molar basis, 6 mg of broluci­zumab equals approximately 12 times the 2.0-mg dose of aflibercept and 22 times the 0.5-mg dose of ranibizumab,” t

 “These attributes may confer potential advantages in the treatment of neovascular AMD. A small molecular weight and high drug concentration gradient between the vitreous and retina may support drug distribution into the retina.

Assuming comparable half-life, higher molar doses of drug may be cleared more slowly from the eye, thus prolonging duration of action,” they explained.

Image result for brolucizumab


این نوشته را با دوستان خود به اشتراک بگذارید


وبسایت دپارتمان شبکیه بیمارستان فارابی – قطب علمی چشم پزشکی ایران

  • ۲
  • ۲۰۵
  • ۶,۱۳۲
  • ۵۱,۶۵۳
  • ۱۸,۷۹۴
  • ۷۰
  • ۳۵۹
  • ۱۴۰۲-۰۶-۲۶